Inflammatory activity assessment by F18 FDG-PET/CT in persistent symptomatic sarcoidosis

Respiratory Medicine

Volumn 105, Issue 12, 2011, Pages 1917-1924

  Mostard, R L M ^a,b   Voo S ^b   Van Kroonenburgh, M J P G ^b   Verschakelen, J A ^c   Wijnen, P A H M ^b   Nelemans, P J ^b   Erckens, R J ^b   Drent, M ^b  

^a Sittard Geleen Heerlen   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Fluorine 18 Fluorodeoxyglucose (F 18 FDG); Inflammation; Positron emission tomography Computed tomography (PET CT); Sarcoidosis; Soluble interleukin 2 receptor

Indexed keywords

C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE; FLUORODEOXYGLUCOSE F 18; METHOTREXATE; NEOPTERIN; PREDNISONE; SOLUBLE INTERLEUKIN 2 RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; HUMAN; INFLAMMATION; LUNG FUNCTION TEST; LUNG SARCOIDOSIS; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SEROLOGY; THORAX RADIOGRAPHY; WHOLE BODY TOMOGRAPHY;

ADULT; AGED; BIOLOGICAL MARKERS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INFLAMMATION; LUNG DISEASES; MALE; MIDDLE AGED; NEOPTERIN; NETHERLANDS; PEPTIDYL-DIPEPTIDASE A; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; QUALITY OF LIFE; RADIOPHARMACEUTICALS; RECEPTORS, INTERLEUKIN-2; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SARCOIDOSIS; SENSITIVITY AND SPECIFICITY; WHOLE BODY IMAGING; YOUNG ADULT;

EID: 81155133749     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2011.08.012     Document Type: Article

References (34)

1. G.W. Hunninghake, U. Costabel, and M. Ando ATS/ERS/WASOG statement on sarcoidosis. American thoracic Society/European respiratory Society/World association of sarcoidosis and other granulomatous disorders Sarcoidosis Vasc Diffuse Lung Dis 16 1999 149 173
2. R.P. Baughman, E.E. Lower, and M. Drent Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them Sarcoidosis Vasc Diffuse Lung Dis 25 2008 76 89
3. Consensus conference: Activity of sarcoidosis. Third WASOG meeting, Los Angeles, USA, September 8-11, 1993. Eur Respir J 1994;7:624-627.
4. R.G. Keijsers, J.F. Verzijlbergen, D.M. van Diepen, J.M. van den Bosch, and J.C. Grutters 18F-FDG PET in sarcoidosis: an observational study in 12 patients treated with infliximab Sarcoidosis Vasc Diffuse Lung Dis 25 2008 143 149
5. M.W. Ziegenhagen, M.E. Rothe, M. Schlaak, and J. Muller-Quernheim Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis Eur Respir J 21 2003 407 413 (Pubitemid 36336197)
6. R.G. Keijsers, F.J. Verzijlbergen, and W.J. Oyen 18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis Eur J Nucl Med Mol Imaging 36 2009 1131 1137
7. C.A. Lazar, and D.A. Culver Treatment of sarcoidosis Semin Respir Crit Care Med 31 2010 501 518
8. J. De Vries, S. Rothkrantz-Kos, M.P. van Dieijen-Visser, and M. Drent The relationship between fatigue and clinical parameters in pulmonary sarcoidosis Sarcoidosis Vasc Diffuse Lung Dis 21 2004 127 136 (Pubitemid 38954753)
9. Marcellis RG, Lenssen AF, Elfferich MD, et al.: Exercise capacity, muscle strength and fatigue in sarcoidosis. Eur Respir J 2011;In press.
10. C. Love, M.B. Tomas, G.G. Tronco, and C.J. Palestro FDG PET of infection and inflammation Radiographics 25 2005 1357 1368 (Pubitemid 41695350)
11. G. El-Haddad, H. Zhuang, N. Gupta, and A. Alavi Evolving role of positron emission tomography in the management of patients with inflammatory and other benign disorders Semin Nucl Med 34 2004 313 329 (Pubitemid 39366000)
12. H. Biller, G. Zissel, and B. Ruprecht Genotype-corrected reference values for serum angiotensin-converting enzyme Eur Respir J 28 2006 1085 1090 (Pubitemid 44883841)
13. H. Tomita, Y. Ina, and Y. Sugiura Polymorphism in the angiotensin-converting enzyme (ACE) gene and sarcoidosis Am J Respir Crit Care Med 156 1997 255 259 (Pubitemid 27293198)
14. M.W. Ziegenhagen, U.K. Benner, and G. Zissel Sarcoidosis: TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers Am J Respir Crit Care Med 156 1997 1586 1592 (Pubitemid 27505529)
15. J.C. Grutters, J.M. Fellrath, and L. Mulder Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis: a clinical evaluation Chest 124 2003 186 195 (Pubitemid 36851351)
16. A. Prasse, C. Katic, and M. Germann Phenotyping sarcoidosis from a pulmonary perspective Am J Respir Crit Care Med 177 2008 330 336 (Pubitemid 351198377)
17. J. Muller-Quernheim Serum markers for the staging of disease activity of sarcoidosis and other interstitial lung diseases of unknown etiology Sarcoidosis Vasc Diffuse Lung Dis 15 1998 22 37 (Pubitemid 28174894)
18. S. Rothkrantz-Kos, M.P. van Dieijen-Visser, P.G. Mulder, and M. Drent Potential usefulness of inflammatory markers to monitor respiratory functional impairment in sarcoidosis Clin Chem 49 2003 1510 1517 (Pubitemid 37011740)
19. J. Bomanji, A. Almuhaideb, and A. Zumla Combined PET and X-ray computed tomography imaging in pulmonary infections and inflammation Curr Opin Pulm Med 17 2011 197 205
20. A.S. Teirstein, J. Machac, and O. Almeida Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis Chest 132 2007 1949 1953
21. J.J. Braun, R. Kessler, A. Constantinesco, and A. Imperiale 18F-FDG PET/CT in sarcoidosis management: review and report of 20 cases Eur J Nucl Med Mol Imaging 35 2008 1537 1543
22. Y. Nishiyama, Y. Yamamoto, and K. Fukunaga Comparative evaluation of 18F-FDG PET and 67Ga scintigraphy in patients with sarcoidosis J Nucl Med 47 2006 1571 1576 (Pubitemid 47545019)
23. R.G. Keijsers, J.C. Grutters, and H. van Velzen-Blad (18)F-FDG PET patterns and BAL cell profiles in pulmonary sarcoidosis Eur J Nucl Med Mol Imaging 37 2010 1181 1188
24. S. Basu, B. Saboury, T. Werner, and A. Alavi Clinical Utility of FDG-PET and PET/CT in Non-malignant thoracic disorders Mol Imaging Biol 2010
25. T. Ishimori, T. Saga, and M. Mamede Increased (18)F-FDG uptake in a model of inflammation: concanavalin A-mediated lymphocyte activation J Nucl Med 43 2002 658 663 (Pubitemid 34507119)
26. M. Drent, J.A. Jacobs, and J. de Vries Does the cellular bronchoalveolar lavage fluid profile reflect the severity of sarcoidosis? Eur Respir J 13 1999 1338 1344 (Pubitemid 29357150)
27. W.P. de Kleijn, M.D. Elfferich, and J. De Vries Fatigue in sarcoidosis: american versus Dutch patients Sarcoidosis Vasc Diffuse Lung Dis 26 2009 92 97
28. E. Hoitsma, J. De Vries, and M. Drent The small fiber neuropathy screening list: Construction and cross-validation in sarcoidosis Respir Med 105 2011 95 100
29. P.H. Quanjer, G.J. Tammeling, and J.E. Cotes Lung volumes and forced ventilatory flows. Report working Party Standardization of lung function tests, European Community for Steel and Coal. Official statement of the European respiratory Society Eur Respir J Suppl 16 1993 5 40
30. D.G. James Complications of sarcoidosis. Chronic fatigue syndrome Sarcoidosis 10 1993 1 3
31. I.H. Korenromp, C.J. Heijnen, O.J. Vogels, J.M. van den Bosch, and J.C. Grutters Characterization of chronic fatigue in sarcoidosis in clinical remission Chest 140 2011 441 447
32. J. Verbraecken, E. Hoitsma, and C.P. Van Der Grinten Sleep disturbances associated with periodic leg movements in chronic sarcoidosis Sarcoidosis Vasc Diffuse Lung Dis 21 2004 137 146 (Pubitemid 38954754)
33. R.P. Baughman, M. Drent, and M. Kavuru Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement Am J Respir Crit Care Med 174 2006 795 802 (Pubitemid 44511661)
34. E. Hoitsma, C.G. Faber, and M. van Santen-Hoeufft Improvement of small fiber neuropathy in a sarcoidosis patient after treatment with infliximab Sarcoidosis Vasc Diffuse Lung Dis 23 2006 73 77 (Pubitemid 44259213)